myelodysplastic syndrome (Cancer)

Search with Google Search with Bing
Information
Disease name
myelodysplastic syndrome
Disease ID
DOID:0050908
Description
"A bone marrow cancer that is characterized by under production of white blood cells, red blood cells and platelets." [url:http\://en.wikipedia.org/wiki/Myelodysplastic_syndrome, url:http\://www.cancer.gov/dictionary?CdrID=45266]
Disease area statistics
Chromosome band
Gene symbol Chromosome Start Stop The number of variant
RUNX1 21 34,787,801 35,049,344 8
KIT 4 54,657,913 54,740,770 4
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT03600155 Active, not recruiting Phase 1 Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome October 11, 2018 March 31, 2026
NCT03560752 Active, not recruiting Phase 1 CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant August 20, 2018 June 18, 2024
NCT02396134 Active, not recruiting Phase 2 Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant May 21, 2015 December 31, 2024
NCT02312102 Active, not recruiting Phase 1 Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation February 2015 August 2024
NCT03404193 Active, not recruiting Phase 2 Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome January 18, 2018 December 31, 2024
NCT02291965 Active, not recruiting Blood Samples to Identify Biomarkers of Busulfan November 2014 May 2025
NCT04188678 Active, not recruiting N/A Resiliency in Older Adults Undergoing Bone Marrow Transplant September 28, 2018 September 30, 2024
NCT05972577 Active, not recruiting N/A Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study June 2, 2021 December 31, 2024
NCT02722668 Active, not recruiting Phase 2 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep May 15, 2017 December 2029
NCT03333486 Active, not recruiting Phase 2 Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer December 7, 2017 August 28, 2024
NCT00392353 Active, not recruiting Phase 1/Phase 2 Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia November 22, 2006 September 30, 2024
NCT02684162 Active, not recruiting Phase 2 Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant June 22, 2016 December 31, 2024
NCT02250937 Active, not recruiting Phase 2 Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome October 27, 2014 October 31, 2025
NCT01885689 Active, not recruiting Phase 2 Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia February 10, 2014 December 30, 2024
NCT03268954 Active, not recruiting Phase 3 Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) November 28, 2017 June 30, 2024
NCT00710892 Active, not recruiting Phase 1 CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene December 2008 July 2026
NCT00719888 Active, not recruiting Phase 2 Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease November 18, 2005 December 22, 2024
NCT05316701 Active, not recruiting Phase 3 Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies June 21, 2022 April 2027
NCT00048958 Active, not recruiting Cytogenetic Studies in Acute Leukemia and Multiple Myeloma June 1984
NCT00525746 Active, not recruiting Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) March 31, 2006 March 31, 2025
NCT04761770 Active, not recruiting Phase 2 Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders February 15, 2021 February 2025
NCT04060277 Active, not recruiting Phase 2 Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation November 27, 2019 April 7, 2030
NCT03862157 Active, not recruiting Phase 1/Phase 2 Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia February 27, 2019 January 31, 2025
NCT03192397 Active, not recruiting Phase 1/Phase 2 Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant August 9, 2017 May 21, 2027
NCT02566304 Active, not recruiting Phase 2 Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies November 13, 2015 February 13, 2024
NCT02530463 Active, not recruiting Phase 2 Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome September 8, 2015 September 30, 2025
NCT02936752 Active, not recruiting Phase 1 Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents June 23, 2017 March 21, 2025
NCT03094637 Active, not recruiting Phase 2 Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome November 6, 2017 November 6, 2023
NCT01746849 Active, not recruiting Phase 2 Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation December 2012 December 2024
NCT00588991 Active, not recruiting Phase 1 Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders November 28, 2007 March 7, 2025
NCT02935361 Active, not recruiting Phase 1/Phase 2 Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed November 2, 2016 November 30, 2025
NCT02521493 Active, not recruiting Phase 3 Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome December 23, 2015 June 30, 2024
NCT04339101 Active, not recruiting Phase 2 Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation November 11, 2020 May 22, 2024
NCT04281199 Active, not recruiting Phase 1 TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT February 28, 2020 December 30, 2024
NCT03092674 Active, not recruiting Phase 2/Phase 3 Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome February 2, 2018 October 29, 2024
NCT01522976 Active, not recruiting Phase 2 Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia March 1, 2012 March 7, 2025
NCT00819546 Active, not recruiting Phase 1 RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS January 2009 December 2025
NCT02861417 Active, not recruiting Phase 2 Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant August 5, 2016 August 31, 2025
NCT02506933 Active, not recruiting Phase 2 Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant November 5, 2015 December 30, 2024
NCT01494103 Active, not recruiting Phase 1 Administration of Donor T Cells With the Caspase-9 Suicide Gene November 2011 May 2029
NCT00843882 Active, not recruiting Phase 3 Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia January 29, 2009 September 21, 2024
NCT02737462 Active, not recruiting Phase 1/Phase 2 Phase 1/2 Study of CG200745 PPA for Myelodysplastic Syndrome June 2016 December 2023
NCT00412360 Completed Phase 3 Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) December 2006 October 2014
NCT00414310 Completed Phase 2 Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) December 2006 May 2015
NCT00418951 Completed Phase 2 Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections November 2006 October 2009
NCT00422032 Completed Phase 2 2 Arm Study of Clofarabine IV in MDS Patients January 2006 November 2011
NCT00422890 Completed Phase 3 Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®) January 2007
NCT00433745 Completed Phase 2 Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy February 2007 November 2009
NCT00452660 Completed Phase 4 Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load May 2007 August 2008
NCT00459524 Completed Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) April 2004 March 2009
NCT00460694 Completed Phase 1/Phase 2 Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies August 2006 December 2012
NCT00462761 Completed Phase 1 A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status January 2007 December 2009
NCT00469014 Completed Phase 2 Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia September 2006 March 2013
NCT00469144 Completed Phase 3 IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome June 2005 November 2014
NCT00487448 Completed Phase 4 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia July 1998 June 2007
NCT00488436 Completed Phase 4 Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome May 2002 December 2007
NCT00491634 Completed Phase 2 Treosulfan-based Conditioning for Transplantation in AML/MDS June 2007 June 2014
NCT00498316 Completed Phase 1 Cord Blood Expansion on Mesenchymal Stem Cells July 3, 2007 October 2016
NCT00504920 Completed Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients May 2004 September 2008
NCT00510315 Completed Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant July 2007 January 2016
NCT00520130 Completed Phase 1/Phase 2 Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System October 30, 2007 December 31, 2018
NCT00520468 Completed Phase 2 Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS June 2004 June 2009
NCT00533923 Completed Phase 2 Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders December 2002 January 2007
NCT00539695 Completed Phase 2 Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD June 2007 March 2014
NCT00556452 Completed Phase 1/Phase 2 Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen October 2007 September 2012
NCT00569010 Completed Phase 1/Phase 2 Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) December 2005 October 2009
NCT00582933 Completed Phase 2 Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor May 2001 April 2009
NCT00587054 Completed Phase 2 Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders June 2001 May 2011
NCT00597519 Completed Phase 2 A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy March 2006 September 2015
NCT00606216 Completed Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy January 2007 December 2015
NCT00619099 Completed Phase 2 A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) May 2008
NCT00620633 Completed Phase 1 Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation February 8, 2008 February 26, 2021
NCT00621023 Completed Phase 2 Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome November 2007 April 2010
NCT00640796 Completed Phase 1 Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors September 2008 April 2014
NCT00648037 Completed N/A Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT March 2008 December 2008
NCT00656448 Completed Phase 3 A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS March 2008 June 2013
NCT00672165 Completed Phase 1 Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies July 2005 February 2015
NCT00674479 Completed Phase 2 INCB018424 in Patients With Advanced Hematologic Malignancies May 12, 2008 March 23, 2017
NCT00686556 Completed Phase 1 Total Marrow Irradiation for Refractory Acute Leukemia August 2012 December 2016
NCT00687323 Completed Phase 2 Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052) July 30, 2007 December 23, 2012
NCT00689000 Completed Phase 1/Phase 2 Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) May 2006 December 2007
NCT00697671 Completed Phase 1 Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies March 2007 May 2013
NCT00697684 Completed Phase 1 Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant June 2008 November 2023
NCT00709592 Completed Phase 2 Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT July 21, 2008 June 28, 2017
NCT00721214 Completed Phase 2 5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome July 2008 June 2014
NCT00723099 Completed Phase 2 Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer June 25, 2008 July 31, 2018
NCT00723112 Completed The Role of Erythropoietin in Myelodysplastic Syndrome February 2007 October 2010
NCT00739141 Completed Phase 2 Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. August 12, 2008 October 15, 2021
NCT00741234 Completed Phase 1 A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine April 2007 March 2012
NCT00744757 Completed Phase 2 An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS) August 2008 August 2012
NCT00760084 Completed Phase 2 Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome July 2005 February 2008
NCT00764829 Completed Blood Samples to Evaluate Biomarkers of Donor Chimerism September 2008 February 2012
NCT00774046 Completed Phase 2 High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML December 2002 March 2011
NCT00774280 Completed Phase 3 Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen May 2002 December 2010
NCT00778375 Completed Phase 2 Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) October 2008 January 2015
NCT00795548 Completed Phase 2 Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation November 2008 August 2011
NCT00796003 Completed Phase 1 A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome July 2008 October 2010
NCT00806598 Completed Phase 2 Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome May 2005 June 2012
NCT00807677 Completed Phase 1 A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies March 2009 March 2013
NCT00809276 Completed Phase 1/Phase 2 Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY May 2009 December 2011
NCT00001623 Completed N/A Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia March 27, 1997 August 3, 2017
NCT00822393 Completed Phase 3 Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC) November 24, 2008 January 25, 2018
NCT00831766 Completed Phase 1/Phase 2 Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) June 25, 2009 November 16, 2020
NCT00852163 Completed Phase 2 Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan Regimen March 2007 December 2011
NCT00809367 Completed N/A Collection and Banking of Leukemia Cells MDS/AML October 2008 May 2011
NCT00001637 Completed Phase 2 Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults September 29, 1997 December 28, 2016
NCT00001873 Completed Phase 2 The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers February 22, 1999 June 13, 2017
NCT00003838 Completed Phase 2 Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow April 15, 1999 June 18, 2020
NCT00004997 Completed Phase 2 Leucovorin for the Treatment of 5 q Minus Syndrome April 1998 July 2002
NCT00005937 Completed Phase 2 Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia June 2000 March 2008
NCT00013533 Completed Early Phase 1 Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies March 14, 2001 May 7, 2015
NCT00038831 Completed Phase 1/Phase 2 Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS May 2001 October 2006
NCT00043381 Completed Phase 3 Decitabine Versus Supportive Care in Adults With Advanced-stage MDS April 2001 April 2003
NCT00044382 Completed Phase 2 Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome February 1, 2002 January 30, 2007
NCT00045786 Completed Phase 2 Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes October 2001 November 2003
NCT00050154 Completed Phase 2 Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS) July 2002 May 2006
NCT00064584 Completed Phase 1 Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) May 2002 July 2005
NCT00067028 Completed Phase 2 Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) December 2003 June 2013
NCT00067808 Completed Phase 2 Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) October 2003 May 2009
NCT00071006 Completed Phase 2 AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) September 2003 July 2004
NCT00088218 Completed Phase 2 Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS). July 2004 February 2008
NCT00089596 Completed Phase 1/Phase 2 Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers March 2004 October 2006
NCT00101179 Completed Phase 1 MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia November 3, 2004 February 3, 2014
NCT00110266 Completed Phase 2 Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients July 25, 2005 March 28, 2008
NCT00136461 Completed Phase 2 A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) May 1997 August 2000
NCT00143559 Completed Phase 2 Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies August 2005 January 2009
NCT00144703 Completed Phase 2 Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation July 2002 November 2006
NCT00152139 Completed Phase 3 Stem Cell Transplantation for Patients With Hematologic Malignancies May 2002 January 2009
NCT00195000 Completed Phase 2 Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS May 2003 February 2008
NCT00195104 Completed Phase 1/Phase 2 Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML September 17, 2003 June 20, 2006
NCT00260065 Completed Phase 2 A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes May 2005 December 2008
NCT00270881 Completed Phase 1/Phase 2 Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies January 2006 January 2011
NCT00283114 Completed Phase 1 A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome November 2005 January 2010
NCT00285259 Completed Phase 2 Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) January 31, 2006 November 30, 2010
NCT00299156 Completed Phase 2 Oral Clofarabine Study in Patients With Myelodysplastic Syndrome March 2006 December 2012
NCT00299767 Completed Phase 1 Phase I Study of Sequential Cord Blood Transplants May 2003 May 2009
NCT00300664 Completed Phase 2/Phase 3 A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. July 2002 April 2005
NCT00324220 Completed Phase 1/Phase 2 A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia January 2006 November 2008
NCT00326170 Completed Phase 2 Phase II 5-Azacytidine Plus VPA Plus ATRA July 2005 December 2007
NCT00350818 Completed Phase 1 Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT) October 2005 August 2010
NCT00360672 Completed Phase 2 Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome January 2009 May 2012
NCT00368355 Completed Phase 2 T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts April 2000 November 2016
NCT00374933 Completed Phase 1 Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation April 2007 December 2009
NCT00378534 Completed Phase 2 Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants September 2006 April 2014
NCT00382590 Completed Phase 2 Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients August 2005 February 2008
NCT00402558 Completed Phase 1 Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) May 2006 April 2014
NCT00854945 Completed Phase 1/Phase 2 Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML January 2009 February 2014
NCT00867230 Completed Phase 1 FTS Study in Patients With Advanced Hematologic Malignancies May 2006 February 2009
NCT00875693 Completed Phase 1 A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML) June 2, 2009 December 27, 2017
NCT00882102 Completed Phase 2 Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) April 2009 August 2012
NCT00892190 Completed Phase 1 Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome April 2011 February 2016
NCT00897130 Completed Phase 2 5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs) August 2008 December 2014
NCT00903422 Completed Phase 1 Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS) May 14, 2009 December 5, 2013
NCT00903760 Completed Phase 2 Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS) January 2010 June 2015
NCT00906334 Completed Phase 2 Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk May 2009 November 2013
NCT00908167 Completed Phase 1 Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies September 2009 June 2015
NCT00911066 Completed Phase 1 MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia June 2009 October 2013
NCT00941109 Completed Phase 1 Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS) December 2009 September 2012
NCT00943800 Completed N/A Combined Haploidentical-Cord Blood Transplantation for Adults and Children October 9, 2006 September 2018
NCT00954720 Completed Observational Study of Iron Overload in Stem Cell Transplantation March 2008 May 2011
NCT00954941 Completed Phase 2 Ondansetron Versus Aprepitant Plus Ondansetron for Emesis November 2009 May 2015
NCT00968071 Completed Phase 2 Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome February 2008 August 2012
NCT00977548 Completed Phase 2 Erlotinib Study for Myelodysplastic Syndrome (MDS) September 2009 June 2012
NCT00987480 Completed Phase 2 Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine September 25, 2009 July 10, 2017
NCT01020175 Completed Phase 3 Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation January 1995 December 2002
NCT01020539 Completed Phase 1 Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia September 11, 2002 December 2020
NCT01041846 Completed A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome December 2008 July 2010
NCT01048034 Completed Phase 2 Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) January 2010 August 2012
NCT01048619 Completed Phase 1 Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome December 2009 December 2015
NCT01062152 Completed Phase 1 Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS) November 2009 March 2013
NCT01062490 Completed Phase 2 Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS) November 2004 October 2009
NCT01063257 Completed Phase 1/Phase 2 Clofarabine in High Risk Myelodysplastic Syndrome (MDS) April 2010 March 2014
NCT01068301 Completed Phase 1 A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation May 2010 October 2013
NCT01075425 Completed Phase 1 Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome May 2010 February 2015
NCT01085838 Completed Phase 1/Phase 2 Erlotinib in Higher Risk Myelodysplastic Syndrome July 2010 March 2014
NCT01099267 Completed Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003 March 1, 2010 October 1, 2010
NCT01099917 Completed Phase 2 Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients? April 2010 September 2014
NCT01119066 Completed Phase 2 HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies May 3, 2010 March 30, 2021
NCT01133275 Completed Phase 2 Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS April 28, 2010 November 21, 2019
NCT01141959 Completed Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients May 2010 December 2011
NCT01152346 Completed Phase 1 Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients April 2011 May 2013
NCT01159028 Completed Phase 1 Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS June 2010 March 30, 2017
NCT01168219 Completed Phase 2 Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia July 15, 2010 February 1, 2020
NCT01169012 Completed Phase 1 PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias September 2010 January 2013
NCT01174888 Completed Phase 1 Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia August 2010 May 2016
NCT01188798 Completed Phase 3 Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies September 2010 February 2012
NCT01200355 Completed Phase 4 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome September 9, 2010 April 3, 2018
NCT01231412 Completed Phase 3 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant November 2010 June 30, 2017
NCT01243476 Completed Phase 3 Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome January 2010 June 6, 2022
NCT01249820 Completed Phase 2 Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease November 2010 January 2013
NCT01250951 Completed Phase 4 This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. December 2009 September 2011
NCT01272817 Completed N/A Nonmyeloablative Allogeneic Transplant October 2001 October 2015
NCT01290302 Completed Phase 1 Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia October 2010
NCT01295710 Completed Phase 3 Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) October 10, 2011 October 15, 2015
NCT01305460 Completed Phase 1/Phase 2 Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS) July 5, 2011 November 16, 2015
NCT01323920 Completed Phase 2 Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors May 2011 November 2013
NCT01336712 Completed Phase 2 Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases April 2011 July 2015
NCT01338987 Completed Phase 2 Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation April 19, 2011 November 19, 2020
NCT01347944 Completed MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry January 1, 2011 June 30, 2013
NCT01362985 Completed Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor July 2009 July 2014
NCT01370213 Completed Phase 2 NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases September 2011 April 2017
NCT01385423 Completed Phase 1 Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) September 2011 March 2015
NCT01398462 Completed Phase 1 Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients July 2011 December 2015
NCT01399840 Completed Phase 1 Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies June 30, 2011 May 31, 2014
NCT01404741 Completed Phase 2 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS) July 2011 July 2021
NCT01433965 Completed Phase 1 Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome August 8, 2012 January 12, 2021
NCT01455506 Completed Phase 1 PRO#0118: Decitabine Plus Mini Flu-Bu May 2009 December 2013
NCT01462578 Completed Phase 2 Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza) September 2011 February 2021
NCT01474681 Completed Phase 1/Phase 2 Safety and Tolerability of HSC835 in Patients With Hematological Malignancies January 9, 2012 October 3, 2016
NCT01481220 Completed Phase 1 Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS) October 2011 May 2013
NCT01491958 Completed Phase 2 Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation December 10, 2011 June 27, 2016
NCT01541280 Completed Phase 2 VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome November 2011 July 2015
NCT01542944 Completed Phase 2 TevaGastrim for Stem Cell Mobilization Sibling Donors February 2012 April 2016
NCT01566695 Completed Phase 3 The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS) April 26, 2013 December 21, 2023
NCT01572662 Completed Phase 2 Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning April 11, 2012 August 11, 2022
NCT01584531 Completed Phase 2 Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome May 2012 November 2015
NCT01586455 Completed Phase 1 Human Placental-Derived Stem Cell Transplantation April 2013 September 2022
NCT01593670 Completed Phase 2 Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes March 2013 October 23, 2018
NCT01597219 Completed Phase 2 Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers March 2013 January 2024
NCT01602211 Completed Phase 3 INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant May 14, 2013 November 28, 2016
NCT01611298 Completed N/A Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR March 2008 July 2013
NCT01634217 Completed Phase 1 Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation November 8, 2013 December 1, 2018
NCT01643668 Completed Phase 2 Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation July 2012 August 2016
NCT01664897 Completed Phase 2 Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia May 16, 2013 October 25, 2018
NCT01682226 Completed Phase 2 Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies September 5, 2012 January 8, 2021
NCT01683123 Completed Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT July 2007 October 2012
NCT01684150 Completed Phase 1 A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving September 2012 February 2016
NCT01690520 Completed Phase 2 Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes December 11, 2012 May 29, 2020
NCT01696461 Completed Phase 2 A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor May 2013 August 2016
NCT01700335 Completed Phase 1 Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) June 2012 February 2015
NCT01700673 Completed Phase 2 Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS June 2013 June 2020
NCT01736436 Completed Phase 1 APG101 in Myelodysplastic Syndrome January 2013 December 2015
NCT01739452 Completed Spanish Registry of Erythropoietic Stimulating Agents Study January 2013 September 2014
NCT01751867 Completed Phase 3 An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome August 2009 April 2013
NCT01757639 Completed Phase 1 Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia December 14, 2012
NCT01760655 Completed Phase 2 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies December 24, 2012 December 5, 2022
NCT01768845 Completed N/A Unrelated Umbilical Cord Blood (UBC)Transplantation February 3, 2009 April 6, 2021
NCT01794299 Completed Phase 2 Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor March 2013 September 2017
NCT01804101 Completed N/A Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia May 7, 2013 January 10, 2017
NCT01812252 Completed Phase 2 Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant August 19, 2013 October 26, 2022
NCT01819558 Completed Phase 1/Phase 2 Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy March 2013 March 2015
NCT01823198 Completed Phase 1/Phase 2 Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies June 11, 2013 May 10, 2022
NCT01828346 Completed Phase 1/Phase 2 Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy June 2013 November 2015
NCT01834248 Completed Phase 1 DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia July 30, 2013 March 21, 2016
NCT01855698 Completed PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism June 2013 March 15, 2018
NCT01873703 Completed Phase 2 Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome June 2013 November 2016
NCT01904136 Completed Phase 1/Phase 2 Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia April 22, 2014 February 28, 2022
NCT01926587 Completed Phase 1/Phase 2 Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine August 2013 February 16, 2021
NCT01930162 Completed Phase 2 Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant October 7, 2014 August 29, 2016
NCT01951430 Completed Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients March 2014 October 29, 2020
NCT01951885 Completed Phase 3 Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention July 7, 2014 August 11, 2021
NCT01953692 Completed Phase 1 A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) November 22, 2013 June 26, 2020
NCT01980056 Completed Phase 1/Phase 2 Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy October 25, 2013 January 19, 2015
NCT01993641 Completed Phase 2 Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA December 2013 June 2016
NCT02000154 Completed Phase 1 Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study December 2014 May 2015
NCT02002936 Completed Phase 1 Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study August 2013 December 2014
NCT02014051 Completed Phase 1 Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) March 2013 November 2014
NCT02017457 Completed Phase 2 Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. December 2013 November 2019
NCT02018926 Completed Phase 1/Phase 2 Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS December 2013 September 2015
NCT02046122 Completed Phase 1/Phase 2 Adoptive Transfer of Haplo-identical DLI for AML and MDS July 2014 July 31, 2019
NCT02057185 Completed Occupational Status and Hematological Disease September 8, 2014 November 11, 2015
NCT02060409 Completed Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome January 2012 February 2014
NCT02065154 Completed Phase 2 Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis August 27, 2013 April 2022
NCT02083250 Completed Phase 1 Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant March 6, 2014 November 12, 2021
NCT02085798 Completed Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment) December 17, 2012 December 14, 2018
NCT02103478 Completed Phase 1/Phase 2 Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) October 28, 2014 December 4, 2019
NCT02117219 Completed Phase 1 Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome May 20, 2014 April 30, 2019
NCT02117297 Completed Phase 2 SCT Plus Immune Therapy in Average Risk AML/MDS January 12, 2012 March 30, 2023
NCT02121418 Completed N/A Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm June 2014 February 14, 2018
NCT02129101 Completed Phase 1 Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies May 2014 October 25, 2019
NCT02129582 Completed Phase 1 Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies November 5, 2014 March 5, 2020
NCT02137629 Completed Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea December 27, 2010 May 19, 2016
NCT02169791 Completed Phase 2 Nonmyeloablative Haploidentical Transplant Followed by MLN9708 July 15, 2014 July 28, 2020
NCT02188290 Completed Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation September 2014 June 2015
NCT02190695 Completed Phase 2 Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS April 1, 2013 April 16, 2020
NCT02203825 Completed Phase 1 Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands March 2015 March 2018
NCT02221310 Completed Phase 2 Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS December 7, 2011 April 4, 2023
NCT02262312 Completed Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome September 2014
NCT02279654 Completed Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) December 17, 2014 March 29, 2022
NCT02296242 Completed Phase 1/Phase 2 Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes November 2014 June 15, 2017
NCT02363491 Completed Phase 1/Phase 2 A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome January 2015 December 2018
NCT02367456 Completed Phase 1 A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients April 28, 2015 March 7, 2022
NCT02397720 Completed Phase 2 Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia April 7, 2015 October 9, 2023
NCT02424968 Completed Phase 2 CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma June 2015 April 2021
NCT02436252 Completed Phase 1/Phase 2 Study of DSP-7888 in Patients With Myelodysplastic Syndrome May 2015 March 2020
NCT02447666 Completed Phase 2 Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) September 15, 2015 May 24, 2019
NCT02452346 Completed Phase 2 Study of Clinical Efficacy and Safety of Tosedostat in MDS March 20, 2015 October 25, 2017
NCT02458235 Completed Phase 2 Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation June 2, 2015 March 15, 2019
NCT02464657 Completed Phase 1/Phase 2 Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) July 2015 May 7, 2020
NCT02485535 Completed Phase 1 Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant September 4, 2015 July 2020
NCT02487069 Completed N/A Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy June 2015 February 29, 2020
NCT02492737 Completed Phase 1 Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation August 7, 2015 March 21, 2018
NCT02500550 Completed Phase 2 Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor October 9, 2015 December 17, 2018
NCT02543879 Completed Phase 1 Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies September 2015 March 2019
NCT02556931 Completed Phase 2 Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies December 2015 April 2021
NCT02566395 Completed Phase 3 Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies December 2014 February 14, 2022
NCT02581007 Completed Phase 2 Reduced Intensity Conditioning Transplant Using Haploidentical Donors October 26, 2015 December 28, 2020
NCT02598752 Completed Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation November 2015 April 10, 2020
NCT02639559 Completed Phase 2 Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies March 31, 2016 April 7, 2023
NCT02678338 Completed Phase 1 CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies November 2015 February 2019
NCT02719574 Completed Phase 1/Phase 2 Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation April 2016 January 24, 2024
NCT02719821 Completed N/A Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation March 2016 June 2, 2017
NCT02728050 Completed Phase 1/Phase 2 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome December 1, 2016 April 4, 2023
NCT02732184 Completed Phase 2 A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS August 2016 December 2017
NCT02744742 Completed Phase 2/Phase 3 G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT April 18, 2016 September 30, 2021
NCT02750995 Completed Phase 1 Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML April 2016 June 1, 2019
NCT02756572 Completed Phase 2 Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms September 22, 2016 July 1, 2020
NCT02767388 Completed Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery September 1, 2016 March 15, 2018
NCT02807558 Completed Phase 2 A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome September 20, 2016 January 25, 2023
NCT02809222 Completed N/A Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls October 25, 2016 March 1, 2021
NCT02842827 Completed Phase 1/Phase 2 A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) October 6, 2016 October 30, 2018
NCT02877277 Completed N/A Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot Study August 8, 2016 May 29, 2017
NCT02890758 Completed Phase 1 Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 May 22, 2018 February 17, 2023
NCT02960646 Completed Phase 1 Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies January 18, 2017 February 13, 2023
NCT03019939 Completed Phase 2 Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia March 28, 2017 August 10, 2020
NCT03047993 Completed Phase 1/Phase 2 Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome November 15, 2017 March 16, 2023
NCT03072043 Completed Phase 1/Phase 2 Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms May 18, 2017 December 8, 2021
NCT03096782 Completed Phase 2 Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma October 13, 2017 September 20, 2022
NCT03128359 Completed Phase 2 High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant May 30, 2017 September 15, 2021
NCT03303066 Completed Phase 2/Phase 3 Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS) June 6, 2018 February 8, 2023
NCT03337451 Completed Phase 1/Phase 2 Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome February 27, 2018 January 10, 2019
NCT03358719 Completed Phase 1 DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia March 27, 2018 August 25, 2021
NCT03359460 Completed Phase 1 Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome December 1, 2017 November 17, 2019
NCT03495167 Completed Phase 1 Study of SyB C-1101 in Patients With Myelodysplastic Syndrome October 6, 2017 May 28, 2019
NCT03941769 Completed Phase 1/Phase 2 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II September 29, 2020 March 1, 2023
NCT04022785 Completed Phase 1 PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome September 9, 2019 October 24, 2022
NCT04079296 Completed Phase 1/Phase 2 A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) September 19, 2019 April 21, 2023
NCT04146038 Completed Phase 2 Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease October 26, 2020 October 25, 2022
NCT04439006 Completed Phase 1 Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization October 23, 2020 September 20, 2022
NCT04484532 Completed Early Phase 1 Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers October 17, 2017 June 7, 2022
NCT04515914 Completed Clinical Relevance of DNMT and HDAC Gene SNP on the Response to Decitabine Therapy for Myelodysplastic Syndrome September 2009 November 2010
NCT04666025 Completed SARS-CoV-2 Donor-Recipient Immunity Transfer September 23, 2020 May 5, 2023
NCT04842604 Completed Phase 3 Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML May 17, 2021 December 2, 2022
NCT01200017 No longer available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
NCT02258490 No longer available Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation
NCT03724227 No longer available Expanded Access for ACE-011
NCT03939585 Not yet recruiting Phase 1 Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT June 1, 2024 June 1, 2026
NCT06419634 Not yet recruiting Phase 1 Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome May 30, 2024 September 16, 2030
NCT06128070 Not yet recruiting Phase 2 Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome June 14, 2024 October 31, 2027
NCT06265584 Not yet recruiting Phase 2 Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant June 28, 2024 May 2028
NCT03816319 Not yet recruiting Phase 1 TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia August 30, 2024 December 11, 2024
NCT06287944 Not yet recruiting Phase 1 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome June 18, 2024 February 24, 2027
NCT06355583 Not yet recruiting Phase 2 Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial April 15, 2024 May 1, 2027
NCT04802161 Recruiting Phase 2 Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes August 24, 2022 December 31, 2024
NCT05969860 Recruiting Phase 2 At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer August 23, 2023 January 1, 2025
NCT04167696 Recruiting Phase 1 Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 November 25, 2019 February 2035
NCT02727803 Recruiting Phase 2 Personalized NK Cell Therapy in CBT May 19, 2016 May 31, 2025
NCT04859218 Recruiting N/A Revisiting the Universal Donor: Does Exposure to O Blood Products Affect Patient Outcomes? November 2023 December 2024
NCT03246906 Recruiting Phase 2 Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation September 11, 2017 October 11, 2026
NCT04900350 Recruiting Phase 1/Phase 2 A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome June 18, 2021 May 2024
NCT03970096 Recruiting Phase 2 Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) November 19, 2019 December 31, 2028
NCT03661307 Recruiting Phase 1/Phase 2 Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome October 31, 2018 January 1, 2026
NCT03150004 Recruiting Phase 2 Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) June 14, 2017 October 1, 2029
NCT05823714 Recruiting Phase 2 Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT January 20, 2022 January 20, 2026
NCT04994808 Recruiting Phase 2 Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia August 11, 2023 April 3, 2027
NCT03113643 Recruiting Phase 1 SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) June 26, 2017 May 31, 2026
NCT05010122 Recruiting Phase 1/Phase 2 ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome July 8, 2021 January 30, 2025
NCT04195633 Recruiting Phase 2 Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies January 25, 2021 December 31, 2026
NCT01624805 Recruiting Phase 2 Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome June 25, 2012 June 30, 2026
NCT01311258 Recruiting Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome August 2007 August 2025
NCT05115630 Recruiting Phase 1/Phase 2 Off-the-shelf NK Cells + SCT for Myeloid Malignancies April 8, 2022 June 1, 2024
NCT03630991 Recruiting Phase 1 Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy October 11, 2018 April 30, 2025
NCT00900198 Recruiting Collection of Tissue Samples for Cancer Research July 6, 2006
NCT05600894 Recruiting Phase 2 Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm June 27, 2023 August 31, 2025
NCT05139004 Recruiting Phase 1 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome July 19, 2022 December 13, 2024
NCT05564650 Recruiting Phase 1/Phase 2 Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome January 12, 2023 July 2025
NCT05564390 Recruiting Phase 2 MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) February 10, 2025 May 15, 2029
NCT03017820 Recruiting Phase 1 VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma April 4, 2017 April 1, 2032
NCT05364762 Recruiting Phase 2 Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants November 23, 2022 April 28, 2024
NCT05457556 Recruiting Phase 3 Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome March 15, 2023 December 1, 2027
NCT05453552 Recruiting Phase 2/Phase 3 G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT July 1, 2022 December 2024
NCT04493138 Recruiting Phase 1/Phase 2 Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations July 21, 2020 December 31, 2025
NCT05448599 Recruiting Phase 1/Phase 2 A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS July 8, 2022 October 2024
NCT04493164 Recruiting Phase 2 CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome December 30, 2020 June 1, 2025
NCT06329999 Recruiting N/A A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML February 3, 2024 December 31, 2027
NCT04537871 Recruiting Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study November 18, 2020 December 4, 2024
NCT04227847 Recruiting Phase 1 A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies August 7, 2020 November 30, 2026
NCT04635384 Recruiting Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test June 30, 2021 December 31, 2024
NCT04645199 Recruiting National Longitudinal Cohort of Hematological Diseases December 1, 2020 December 1, 2030
NCT04655755 Recruiting Phase 1/Phase 2 Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia January 19, 2021 July 20, 2026
NCT02494167 Recruiting Phase 1 Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) February 2016 February 2026
NCT03622788 Recruiting Phase 1/Phase 2 Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant August 8, 2019 December 1, 2025
NCT06059391 Recruiting Phase 2 CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant August 30, 2024 January 1, 2028
NCT04239157 Recruiting Phase 2 A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia August 25, 2020 December 31, 2026
NCT04243785 Recruiting Phase 1 A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome January 6, 2020 March 2027
NCT04734990 Recruiting Phase 1/Phase 2 Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia July 7, 2021 September 11, 2025
NCT02356159 Recruiting Phase 1/Phase 2 Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation September 24, 2015 December 1, 2024
NCT06063486 Recruiting Phase 2 Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms March 1, 2024 March 1, 2027
NCT03969446 Recruiting Phase 1 Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory May 4, 2020 November 4, 2025
NCT03739502 Recruiting Phase 2 A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant February 28, 2019 April 2026
NCT06013423 Recruiting Phase 2 Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases July 6, 2024 October 31, 2025
NCT06195891 Recruiting Phase 1 Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome September 28, 2024 June 21, 2027
NCT04282187 Recruiting Phase 2 Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms March 24, 2020 November 11, 2026
NCT03672539 Recruiting Phase 2 Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome November 7, 2018 November 30, 2025
NCT04160052 Recruiting Phase 1/Phase 2 Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome October 1, 2019 December 31, 2025
NCT04708054 Recruiting Phase 2 Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS October 21, 2021 December 31, 2024
NCT06034470 Recruiting Phase 1 Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms December 18, 2023 December 31, 2027
NCT04713956 Recruiting Phase 2/Phase 3 G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT January 15, 2021 July 31, 2024
NCT04726241 Recruiting Phase 1/Phase 2 The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study April 18, 2022 December 31, 2026
NCT03683433 Recruiting Phase 2 Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation September 18, 2018 September 20, 2025
NCT06073860 Recruiting A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia November 2, 2023 September 27, 2029
NCT02508038 Recruiting Phase 1 Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors February 12, 2016 December 2025
NCT04262843 Recruiting Phase 2 Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia February 7, 2020 August 4, 2025
NCT04278768 Recruiting Phase 1/Phase 2 Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS July 6, 2020 April 1, 2026
NCT02115295 Recruiting Phase 2 Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia May 19, 2014 May 31, 2026
NCT04279847 Recruiting Phase 1 Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms February 23, 2021 December 31, 2024
NCT03494569 Recruiting Phase 1 Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome July 6, 2018 November 11, 2028
NCT03471260 Recruiting Phase 1/Phase 2 Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies March 19, 2018 September 30, 2025
NCT03770429 Recruiting Phase 1 AZD6738 for Patients With Progressive MDS or CMML August 5, 2019 May 31, 2025
NCT03399773 Recruiting Phase 2 Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes May 10, 2022 June 30, 2026
NCT00329498 Suspended Phase 2 L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes May 1998 August 2005
NCT01010373 Suspended Phase 2 Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients January 2015 January 2016
NCT05823480 Suspended Phase 1 Magrolimab in Combination With Azacitidine After Allogeneic HCTin Treating Patients With High-Risk AML or MDS June 9, 2024 May 3, 2025
NCT01709396 Suspended Phase 2 ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS January 2012 January 2018
NCT03326921 Suspended Phase 1 HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant February 23, 2018 July 16, 2028
NCT01111448 Terminated Phase 2 Temsirolimus in Myelodysplastic Syndrome (MDS) April 2010 June 2014
NCT02065869 Terminated Phase 1/Phase 2 Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant April 2014 September 7, 2021
NCT04083170 Terminated Phase 2 Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers October 6, 2022 November 30, 2022
NCT00113828 Terminated Phase 2 Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies December 2004 March 2007
NCT02181699 Terminated Phase 1 Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) June 2014 May 10, 2019
NCT02226497 Terminated N/A Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy January 9, 2015 August 30, 2018
NCT00699842 Terminated Phase 1/Phase 2 A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients July 2008 May 2012
NCT00674427 Terminated Phase 1 Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant January 2008 January 2012
NCT00669890 Terminated Phase 1 Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML May 2004 December 2013
NCT02319369 Terminated Phase 1 Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) November 25, 2014 August 21, 2020
NCT02360111 Terminated N/A GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant February 2015 September 2017
NCT00113646 Terminated Phase 2 Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies November 2002 December 2007
NCT00852709 Terminated Phase 1 Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias September 1, 2007 November 20, 2009
NCT02381548 Terminated Phase 1 Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia August 18, 2015 May 23, 2018
NCT00867308 Terminated Phase 2 Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia July 2009 May 2014
NCT00658411 Terminated N/A Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation August 2008 December 2011
NCT00113321 Terminated Phase 2 Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure March 2005 November 2008
NCT00893997 Terminated Phase 2 PR1 Vaccination in Myelodysplastic Syndrome (MDS) July 2006 March 2009
NCT00939159 Terminated Phase 2 Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) August 2009 June 2013
NCT00965861 Terminated SCRI Tissue Testing Registry May 2010 February 2013
NCT00967343 Terminated Phase 2/Phase 3 Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor August 2009 February 2012
NCT00967525 Terminated N/A Intraosseous Infusion of Unrelated Cord Blood Grafts March 2007 July 2011
NCT00968864 Terminated Phase 2 T-cell Depleted Alternative Donor Transplantation August 2009 November 2016
NCT00626626 Terminated Phase 1/Phase 2 Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation May 2007 January 2010
NCT01003678 Terminated Phase 1 Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients October 2009 October 2013
NCT02508324 Terminated Phase 2 IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia September 10, 2015 June 24, 2022
NCT02520427 Terminated Phase 1 A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies October 20, 2015 January 9, 2022
NCT01028716 Terminated Phase 2 Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies May 19, 2010 October 7, 2021
NCT01039350 Terminated Phase 2 Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients. February 2006 July 2009
NCT04691141 Terminated Phase 1/Phase 2 A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) February 23, 2021 September 19, 2023
NCT02562443 Terminated Phase 3 Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA December 2, 2015 July 26, 2021
NCT00074490 Terminated Phase 2 Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers January 1, 2004 August 16, 2017
NCT02663752 Terminated Phase 2 A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy. May 30, 2016 July 1, 2016
NCT02676323 Terminated Phase 1 Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome May 3, 2016 April 9, 2018
NCT04762875 Terminated Phase 2 MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies June 16, 2021 March 14, 2022
NCT01135329 Terminated Phase 2 Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers August 2010 May 2012
NCT02683395 Terminated Phase 1 A Study of PLX51107 in Advanced Malignancies March 2016 September 2018
NCT00506948 Terminated Phase 2 Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD) September 2006 October 2010
NCT02706899 Terminated Phase 1/Phase 2 Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS February 2016 November 6, 2017
NCT00495547 Terminated Phase 2 SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome February 2009 June 2011
NCT01207076 Terminated Phase 1 AHN-12 Biodistribution in Advanced Leukemia December 2013 July 2014
NCT00467610 Terminated Phase 2 Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS May 2007 January 2009
NCT02743611 Terminated Phase 1/Phase 2 Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma April 14, 2017 July 19, 2020
NCT02750254 Terminated Phase 1 Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation June 27, 2016 October 14, 2020
NCT01300611 Terminated Phase 1 TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation January 2011 December 2020
NCT01326845 Terminated Phase 4 Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study December 2011 September 2012
NCT01333449 Terminated Phase 2 Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients July 2010 August 2013
NCT01366612 Terminated Phase 3 PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation June 16, 2010 August 18, 2020
NCT02877082 Terminated Phase 2 Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients September 2016 July 2017
NCT02929498 Terminated Phase 1/Phase 2 Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS) July 31, 2017 January 31, 2018
NCT00458159 Terminated Phase 1 A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes May 1, 2007 December 1, 2008
NCT00443300 Terminated Effectiveness of Protected Environment Rooms for AML and MDS January 2007 January 2008
NCT02943668 Terminated Phase 2 Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome March 2, 2017 December 17, 2018
NCT00840827 Terminated Phase 2 Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes December 2008 December 2010
NCT01500161 Terminated Phase 2 Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match November 2011 November 2013
NCT01513317 Terminated Phase 2 A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome November 2011 September 2012
NCT00818649 Terminated Phase 2 Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia January 2009 May 2012
NCT02999854 Terminated Phase 3 Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer November 29, 2017 December 17, 2021
NCT01598025 Terminated N/A Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor May 2, 2012 October 16, 2017
NCT00306332 Terminated Phase 3 T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation March 2006
NCT01615146 Terminated N/A Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot June 2012 June 2015
NCT01621477 Terminated Phase 2 T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant August 2012 December 2015
NCT01624701 Terminated Phase 1/Phase 2 Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells March 2012 July 2016
NCT01643603 Terminated Phase 1 Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies May 2012 October 9, 2018
NCT01663766 Terminated Phase 1 Phase I Study of Milatuzumab for Graft Versus Host Disease December 2013 March 2015
NCT01685411 Terminated N/A Busulfan and Cyclophosphamide Followed By ALLO BMT January 2013 February 10, 2020
NCT03195010 Terminated Phase 2 Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia June 9, 2017 December 21, 2018
NCT00282399 Terminated Phase 1 A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome October 2006 February 2009
NCT03272633 Terminated Early Phase 1 Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies October 26, 2020 September 22, 2022
NCT01745913 Terminated Phase 2 Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies October 26, 2012 April 29, 2015
NCT00790855 Terminated Phase 1/Phase 2 Bendamustine in Acute Leukemia and MDS November 2008 March 2012
NCT01748240 Terminated Phase 2 Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure March 2013 July 2015
NCT01749111 Terminated Phase 3 Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis December 2012 August 2016
NCT00271804 Terminated Phase 1 Study of Velcade and Thalidomide in Patients With Myelodysplasia June 2005 April 2007
NCT00043810 Terminated Phase 1/Phase 2 Study of Gelonin Purging of Autologous Stem Cells for Transplantation July 2002 March 2005
NCT01773395 Terminated Phase 2 GVAX vs. Placebo for MDS/AML After Allo HSCT January 8, 2013 November 24, 2021
NCT01795924 Terminated Phase 1/Phase 2 Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome January 2013 November 2014
NCT00251511 Terminated Phase 2 A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome August 2004 May 2007
NCT03465540 Terminated Phase 1 Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies August 17, 2018 July 25, 2019
NCT00167180 Terminated Phase 2 Post Transplant Donor Lymphocyte Infusion January 2004 December 24, 2018
NCT01196715 Unknown status Phase 3 Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes November 2010 November 2015
NCT01277484 Unknown status Phase 1 Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML January 2011 December 2015
NCT01652781 Unknown status Phase 2 5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome March 2012 December 2016
NCT02045654 Unknown status Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic Syndrome January 2014 March 2015
NCT02850822 Unknown status Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCT July 2016 June 2020
NCT01828619 Unknown status Study of New RIC Regimen of BuFlu in Older and/or Intolerable Patients February 2013
NCT01509300 Unknown status Phase 1/Phase 2 HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors January 2012 March 2014
NCT00598624 Unknown status Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) September 2005 December 2010
NCT01356875 Unknown status Phase 2 Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy September 2011 January 2015
NCT01556477 Unknown status Phase 2 The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q). March 2012 November 2014
NCT00057031 Unknown status Phase 2 Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS) November 2002 March 2004
NCT01339988 Unknown status Phase 4 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) June 2011 June 2019
NCT03088709 Unknown status Phase 2 Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide January 18, 2017 January 31, 2022
NCT00704704 Unknown status Phase 2 Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome) September 2008 April 2011
NCT01331603 Unknown status Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis March 2011 January 2013
NCT01894477 Unknown status Phase 2 Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia November 2013 June 2022
NCT01619761 Unknown status Phase 1 NK Cells in Cord Blood Transplantation May 3, 2013 November 2021
NCT05061147 Unknown status Phase 1/Phase 2 A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) September 16, 2021 October 31, 2022
NCT01291745 Unknown status Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES September 2010 September 2015
NCT01255319 Unknown status Cyclophosphamide, Fludarabine and Antithymocyte Globulin Conditioning in Myelodysplastic Syndrome (MDS) November 2010 November 2014
NCT01673308 Unknown status Phase 2 Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome August 2012 November 2016
NCT01252784 Unknown status Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation November 2010 October 2014
NCT03154190 Unknown status N/A Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer August 8, 2017 August 30, 2022
NCT00304720 Unknown status Phase 2 Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor March 2004
NCT00885508 Unknown status Phase 2 A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q February 2009 December 2015
NCT01240525 Unknown status Phase 2 Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers November 2011 November 2019
NCT01985061 Unknown status Phase 2 Evaluation of 3 Different Doses of IV Busulfan December 2013 December 2018
NCT02330692 Unknown status Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome September 2013 September 2023
NCT00956787 Unknown status Phase 2 Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS) June 2009 December 2014
NCT01716364 Unknown status Phase 1 Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome January 2010 December 2013
NCT01178814 Unknown status Phase 2 Revlimid in Transfusion Dependent Patients July 2010 January 2022
NCT02717884 Unknown status Phase 1/Phase 2 Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) May 2015 December 2021
NCT02272478 Unknown status Phase 2/Phase 3 Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations October 30, 2014 February 2022
NCT02123836 Unknown status Phase 1 Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome April 2014 October 2020
NCT02007811 Unknown status Phase 1/Phase 2 Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination November 2013 December 2015
NCT02013102 Unknown status Phase 4 A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome March 2013 December 2015
NCT00153582 Unknown status Phase 2 WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) April 2002
NCT03800095 Unknown status Phase 3 Early Palliative Care for Patients With Haematological Malignancies March 14, 2019 December 31, 2023
NCT03356080 Unknown status Phase 2 DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess July 7, 2017 July 7, 2020
NCT01133886 Unknown status Phase 2 Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure September 2010 September 2013
NCT02042482 Unknown status Phase 2/Phase 3 The Effect of Combination Ultra Q10 and L-carnitine on the Course of Myelodysplastic Syndrome May 2013 May 2016
NCT00466843 Unknown status Phase 2 Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome April 2007 February 2010
NCT01451268 Unknown status Phase 1/Phase 2 Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) January 2011 April 2018
NCT01053806 Unknown status Phase 2 Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome August 2011
NCT02431351 Withdrawn Phase 2 Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients November 2015 May 2019
NCT03086252 Withdrawn N/A Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study July 24, 2017 May 31, 2018
NCT00226512 Withdrawn Phase 3 To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning July 2004
NCT03438344 Withdrawn Phase 2 Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant December 2018 December 2021
NCT00247026 Withdrawn Phase 1/Phase 2 The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes April 2007
NCT02075034 Withdrawn Phase 1 Three Dosing Schedules of Oral Rigosertib in MDS Patients May 2014 November 2019
NCT03602898 Withdrawn Phase 2 Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation June 1, 2021 September 17, 2023
NCT00867061 Withdrawn Phase 1/Phase 2 Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS) March 2009 September 2010
NCT03066466 Withdrawn Phase 3 Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT December 10, 2019 February 28, 2021
NCT04013880 Withdrawn Phase 1/Phase 2 ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia August 27, 2019 March 31, 2022
NCT00570375 Withdrawn Phase 2 The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome November 2007 April 2009
NCT00570999 Withdrawn Phase 2 Palifermin After Haploidentical PBSCT February 2008 January 2013
NCT02783547 Withdrawn Phase 1 Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome December 2015 June 2017
NCT02923986 Withdrawn Phase 1/Phase 2 Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS September 1, 2017 May 27, 2020
NCT00960726 Withdrawn Phase 2 NOV-002 in Myelodysplastic Syndrome (MDS)
NCT03365661 Withdrawn Phase 2 QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML October 30, 2018 January 1, 2023
Disase is a (Disease Ontology)
DOID:4960
Cross Reference ID (Disease Ontology)
GARD:7132
Cross Reference ID (Disease Ontology)
ICDO:9989/3
Cross Reference ID (Disease Ontology)
MESH:D009190
Cross Reference ID (Disease Ontology)
MIM:614286
Cross Reference ID (Disease Ontology)
UMLS_CUI:C2713368